ARS Pharmaceuticals Reports 114% Revenue Growth to $33.7 Million in Q2 2026

ARS Pharmaceuticals, Inc. reported significant financial results for the second quarter of 2026, with total revenue reaching $33.7 million, a 114% increase from $15.7 million in the same period last year. This growth was primarily driven by a substantial rise in product revenue from neffy, which amounted to $26.2 million, compared to $12.8 million in the prior year. The company also generated $7.4 million from supply agreements, marking a notable increase from $0.3 million in the previous year. However, ARS Pharmaceuticals incurred a net loss of $62.3 million for the quarter, up from a loss of $44.9 million in Q2 2025, reflecting increased operational costs associated with its commercialization efforts.

In the first half of 2026, ARS Pharmaceuticals reported total revenue of $56.3 million, a 138% increase from $23.7 million in the first half of 2025. The company’s product revenue for this period was $43.7 million, up from $20.6 million, while revenue from collaboration agreements decreased slightly to $2.5 million. The increase in revenue was attributed to higher sales volumes of neffy, which has gained traction in the market since its launch. Operating expenses for the first half of 2026 totaled $177.9 million, a 64% increase compared to $108.5 million in the same period last year, driven by higher costs in selling, general, and administrative expenses, which rose to $149.8 million.

Strategically, ARS Pharmaceuticals has made significant strides in expanding its market presence. The company reported that over 35,000 healthcare providers have prescribed neffy, with approximately 40% being repeat prescribers. The total number of patients prescribed neffy reached about 167,000, with a notable increase in market share from 2.5% to 5% in the U.S. epinephrine market. The company has also secured approximately 90% overall commercial coverage for neffy, with ongoing efforts to expand coverage among Medicaid states.

Operationally, ARS Pharmaceuticals has focused on enhancing its commercialization strategy, which includes direct engagement with prescribers and extensive marketing initiatives. The company has also entered into various collaboration agreements to facilitate the distribution of neffy in international markets, including partnerships in Europe, Japan, Australia, and China. As of June 30, 2026, the company had cash, cash equivalents, and short-term investments totaling $143.8 million, which it expects will be sufficient to meet its anticipated cash requirements for at least the next 12 months.

Looking ahead, ARS Pharmaceuticals remains optimistic about the future of neffy and its intranasal epinephrine technology. The company plans to continue its focus on expanding market share and securing favorable insurance coverage while also exploring additional indications for its products. However, the company acknowledges the inherent risks and uncertainties associated with product development and commercialization, which may impact its financial performance in the future.